• ورود
  • هیچ محصولی در سبد خرید نیست.

روند آنلاین سهام XXII

22nd Century Group, Inc

  روند روزانه سهام شرکت

۲۲nd Century Group, Inc

 

finviz dynamic chart for  XXII

این نمودار بصورت روزانه به روز رسانی می گردد

 

 

            نام شرکت                    نماد          سرمایه (میلیون دلار)            کشور        سال عرضه اولیه        زیر مجموعه  
۲۲nd Century Group, Inc XXII ۱۲۴٫۵۳ United States N/A Farming/Seeds/Milling

Company Overview

۲۲nd Century Group, Inc. was incorporated under the laws of the State of Nevada on September 12, 2005 under the name Touchstone Mining Limited. On January 25, 2011, we entered into a reverse merger transaction with 22nd Century Limited, LLC, which we refer to herein as the “merger.” Upon the closing of the merger, 22nd Century Limited, LLC became our wholly-owned subsidiary. After the merger, we succeeded to the business of 22nd Century Limited, LLC as our sole line of business.

۲۲nd Century Limited, LLC was originally formed as a New York limited liability company on February 20, 1998 as 21st Century Limited, LLC and subsequently merged with a newly-formed Delaware limited liability company, 22nd Century Limited, LLC, on November 29, 1999. Since inception, 22nd Century Limited, LLC has sponsored research and subsequently used biotechnology to regulate the nicotine content in tobacco plants.

 Overview

We are a plant biotechnology company focused on technology that allows us to increase or decrease the level of nicotine and other nicotinic alkaloids in tobacco plants and levels of cannabinoids in cannabis plants through genetic engineering and plant breeding. Our primary mission is to reduce the harm caused by smoking. We own or exclusively control more than 200 issued patents plus more than 50 pending patent applications.

We are in the process of transitioning from researching and developing our proprietary technology and tobaccos to commercializing our technology and products. We initiated the commercialization of our technology and products in the year 2015. According to Euromonitor International, annual worldwide tobacco product sales, including cigarettes and smokeless products, are approximately $800 billion, most of which are cigarette sales. If we, or our licensee(s), capture a small fraction of this market, we believe our value will increase tremendously.

We are primarily involved in the following activities:

· The research and development of potentially less harmful or modified risk tobacco products and novel tobacco plant varieties;

· The pursuit of necessary regulatory approvals and clearances from the FDA to market  BRAND A  cigarettes in the U.S. as an over-the-counter product labeled to advertise the reduced exposure to nicotine, as BRAND A cigarettes contain 95% less nicotine than conventional tobacco cigarettes;

· The development of X-22 , a prescription-based smoking cessation aid consisting of very low nicotine (“VLN”) cigarettes, and the pursuit of regulatory approvals and clearances from the FDA and regulatory agencies in other countries to marketX-22 as a prescription smoking cessation aid;

· The pursuit of necessary regulatory approvals and clearances from the FDA to market BRAND B  cigarettes as modified risk cigarettes with an extremely low tar-to-nicotine ratio;

· The manufacture, marketing, sales and distribution of RED SUN and MAGIC proprietary cigarettes;

· The production of SPECTRUM research cigarettes for the National Institute on Drug Abuse (“NIDA”), a part of the National Institutes of Health (“NIH”);

· The international licensing of our technology, proprietary tobaccos, and trademarks;

· The sale of our branded proprietary tobaccos;

· The contract manufacturing of third-party branded tobacco products; and

· The research and development of unique plant varieties of hemp/cannabis, such as (i) plants with low to no amounts of delta-9-tetrahydrocannabinol, or THC, for the legal hemp industry, and (ii) plants with high levels of cannabidiol, or CBD, and other non-THC cannabinoids for the legal medical cannabis markets.

Our prospects depend on our ability to generate and sustain revenues from (i) licensing and/or sale of our proprietary tobacco, technology and products; (ii) regulatory approval of our X-22 smoking cessation aid; (iii) further development of our potential modified risk tobacco products; (iv) domestic and international sales of our brands, including RED SUN and MAGIC ; and (v) the manufacture of the filtered cigar and cigarette brands of third-parties at our manufacturing facility in North Carolina. Our ability to generate meaningful revenue from our potential modified risk tobacco products in the United States depends on obtaining FDA authorization to market these products as modified risk or reduced exposure; and our ability to generate meaningful revenue in the United States from X-2 ۲ depends on FDA approval. If these products are authorized and approved by the FDA, we must still meet the challenges of successful marketing, distribution and consumer acceptance.

27 جولای 2017

۰ پاسخ به "روند آنلاین سهام XXII"

ارسال یک پیغام

این سایت از اکیسمت برای کاهش هرزنامه استفاده می کند. بیاموزید که چگونه اطلاعات دیدگاه های شما پردازش می‌شوند.

preloader